4//SEC Filing
Forman Stephen J. 4
Accession 0001493152-22-021182
CIK 0001335105other
Filed
Aug 2, 8:00 PM ET
Accepted
Aug 3, 4:45 PM ET
Size
13.1 KB
Accession
0001493152-22-021182
Insider Transaction Report
Form 4
Forman Stephen J.
Director
Transactions
- Award
Options to Purchase Common Stock
2022-06-30+100,000→ 100,000 totalExercise: $0.74From: 2022-06-30Exp: 2027-06-30→ Common (100,000 underlying)
Holdings
- 50,000
Options to Purchase Common Stock
Exercise: $3.21From: 2021-01-06Exp: 2026-01-06→ Common (50,000 underlying) - 21,053(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $5.70From: 2018-12-07Exp: 2022-12-07→ Common (21,053 underlying) - 8,333
Options to Purchase Common Stock
Exercise: $6.60From: 2019-05-22Exp: 2024-05-22→ Common (8,333 underlying) - 16,667(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $6.00From: 2018-12-07Exp: 2022-12-07→ Common (16,667 underlying) - 100,000
Options to Purchase Common Stock
Exercise: $3.03From: 2021-06-30Exp: 2026-06-30→ Common (100,000 underlying) - 8,333
Options to Purchase Common Stock
Exercise: $0.90From: 2017-10-16Exp: 2022-10-16→ Common (8,333 underlying)
Footnotes (1)
- [F1]Effective June 30, 2022, the reporting person was granted stock options to purchase an aggregate of 100,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2022).
Documents
Issuer
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
CIK 0001335105
Entity typeother
Related Parties
1- filerCIK 0001676461
Filing Metadata
- Form type
- 4
- Filed
- Aug 2, 8:00 PM ET
- Accepted
- Aug 3, 4:45 PM ET
- Size
- 13.1 KB